# Otsuka Pharmaceutical Development & trials: 297 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 297 trials with Otsuka Pharmaceutical Development & Commercialization, Inc. as lead sponsor, 17 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Otsuka Pharmaceutical Development & Commercialization, Inc.: 297 rows for $14.85, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-development-and-commercialization-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 297
- Recruiting or not yet: 17
- Read on: November 19, 2026

## Trials

The 25 newest of 297, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933445 | VIS954 for Treating Inflammatory Skin Problems | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | Not yet recruiting | Inflammatory Skin Diseases | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933445) |
| October 29, 2026 | NCT07904806 | Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | Not yet recruiting | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07904806) |
| October 7, 2026 | NCT07862959 | Early Access Program for Ulefnersen in Children, Adolescents and Adults With FUS-associated Amyotrophic Lateral Sclerosis (FUS-ALS) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Not applicable | Available | Amyotrophic Lateral Sclerosis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862959) |
| October 6, 2026 | NCT07861113 | A Study to Evaluate the Effectiveness and Safety of Sibeprenlimab in Participants With Primary Membranous Nephropathy, Immune-mediated... | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | Not yet recruiting | Primary Membranous Nephropathy, Minimal Change Disease, Focal Segmental Glomerulosclerosis | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861113) |
| August 26, 2026 | NCT07786454 | A Trial of the Safety and Tolerability of SEP-363856 in Adults With Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Generalized Anxiety Disorder | 1,120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07786454) |
| August 18, 2026 | NCT07770815 | Trial of Sibeprenlimab in Children and Adolescents With Immunoglobulin A Nephropathy (IgAN) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Not yet recruiting | IgA Nephropathy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770815) |
| August 17, 2026 | NCT07767903 | A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Generalized Anxiety Disorder | 384 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767903) |
| August 12, 2026 | NCT07759154 | A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Attention-deficit/Hyperactivity Disorder, Emotional Dysregulation | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759154) |
| August 12, 2026 | NCT07759128 | A Trial of the Efficacy and Safety of Fixed Doses of SEP-363856 in Adults With Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Generalized Anxiety Disorder | 576 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759128) |
| July 20, 2026 | NCT07713758 | A Trial to Examine if Repinatrabit is Processed Differently in Adults With Reduced Liver or Kidney Function Compared to Adults With Normal... | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Phenylketonuria | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713758) |
| June 16, 2026 | NCT07649265 | A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649265) |
| May 7, 2026 | NCT07573449 | How \[14C\]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573449) |
| April 24, 2026 | NCT07549581 | A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549581) |
| April 21, 2026 | NCT07542847 | A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Healthy Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07542847) |
| April 13, 2026 | NCT07525960 | A Study in Adult Males With X-linked Congenital Nephrogenic Diabetes Insipidus to Test the Effects of NDI-5001 Given for Multiple Days and... | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Diabetes Insipidus | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525960) |
| March 23, 2026 | NCT07486895 | Trial to Demonstrate the Equivalence of Two Different Strengths of Oral Centanafadine Capsules in Healthy Subjects | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Healthy Adult Participants | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486895) |
| March 12, 2026 | NCT07465731 | A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Healthy Volunteers | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465731) |
| March 6, 2026 | NCT07455084 | A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Not yet recruiting | Schizophrenia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455084) |
| March 3, 2026 | NCT07446400 | A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and... | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Recruiting | Healthy Volunteers | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446400) |
| January 9, 2026 | NCT07329621 | A Brain Imaging Study to Assess the Binding of MSP-2020 to Serotonin 5-HT2A Receptors in Healthy Male Adults | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Terminated | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07329621) |
| January 2, 2026 | NCT07314333 | A Trial to Assess How Centanafadine Interacts With Stimulants in the Body | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | ADHD | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314333) |
| January 2, 2026 | NCT07314320 | A Study to Detect Radioactivity of \[14C\]-OPC-167832 in Urine and Feces in Healthy Men | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07314320) |
| December 26, 2025 | NCT07305779 | A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Schizophrenia | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07305779) |
| November 28, 2025 | NCT07253441 | A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood... | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 1 | Completed | Attention Deficit Disorder With Hyperactivity | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07253441) |
| October 7, 2025 | NCT07209761 | A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 | Recruiting | Rifampicin-Resistant Pulmonary Tuberculosis, Multidrug-Resistant Pulmonary Tuberculosis | 532 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209761) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 69 |
| Phase 1/2 | 4 |
| Phase 2 | 53 |
| Phase 2/3 | 5 |
| Phase 3 | 138 |
| Phase 4 | 18 |
| Not applicable | 3 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 236 |
| Terminated | 30 |
| Recruiting | 12 |
| Withdrawn | 7 |
| Active not recruiting | 5 |
| Not yet recruiting | 5 |
| Enrolling by invitation | 1 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 88 |
| Depressive Disorder, Major | 36 |
| Mental Disorders | 25 |
| Attention Deficit Disorder with Hyperactivity | 21 |
| Bipolar Disorder | 14 |
| Psychotic Disorders | 14 |
| Alzheimer Disease | 13 |
| Depression | 13 |
| Psychomotor Agitation | 10 |
| Polycystic Kidney, Autosomal Dominant | 10 |
| Hyponatremia | 8 |
| Tuberculosis, Multidrug-Resistant | 7 |
| Nervous System Diseases | 7 |
| Mania | 7 |
| Depressive Disorder | 7 |
| Tourette Syndrome | 6 |
| Phenylketonurias | 6 |
| Mood Disorders | 6 |
| Glomerulonephritis, IGA | 6 |
| Autistic Disorder | 6 |
| Heart Failure | 6 |
| Generalized Anxiety Disorder | 6 |
| Anxiety Disorders | 6 |
| Tuberculosis | 5 |
| Dementia | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Immigration law firms in the United States](https://specstream.ai/data/businesses/immigration-law-firms/united-states)
- [Home cleaning companies in the United States](https://specstream.ai/data/businesses/home-cleaning-companies/united-states)
- [Geriatric medicine practices in the United States](https://specstream.ai/data/businesses/geriatric-medicine-practices/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
